Cybin subsidiary achieved certain milestones as outlined in acquisition agreement Adelia brought numerous advantages to company Acquisition may advance “Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” says CEO Cybin’s (NEO: CYBN) (NYSE American CYBN) most recent acquisition, Adelia Therapeutics Inc., is already reporting success for the company […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.